These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17095052)

  • 1. Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice.
    Xu L; Mei M; Haskins ME; Nichols TC; O'donnell P; Cullen K; Dillow A; Bellinger D; Ponder KP
    Thromb Res; 2007; 120(2):269-80. PubMed ID: 17095052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neonatal gene transfer with a retroviral vector results in tolerance to human factor IX in mice and dogs.
    Zhang J; Xu L; Haskins ME; Parker Ponder K
    Blood; 2004 Jan; 103(1):143-51. PubMed ID: 12969967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B.
    Xu L; Gao C; Sands MS; Cai SR; Nichols TC; Bellinger DA; Raymer RA; McCorquodale S; Ponder KP
    Blood; 2003 May; 101(10):3924-32. PubMed ID: 12531787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
    Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
    Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
    Fields PA; Kowalczyk DW; Arruda VR; Armstrong E; McCleland ML; Hagstrom JN; Pasi KJ; Ertl HC; Herzog RW; High KA
    Mol Ther; 2000 Mar; 1(3):225-35. PubMed ID: 10933938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent expression of canine factor IX in hemophilia B canines.
    Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
    Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
    Cohn EF; Zhuo J; Kelly ME; Chao HJ
    J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice.
    Sabatino DE; Mackenzie TC; Peranteau W; Edmonson S; Campagnoli C; Liu YL; Flake AW; High KA
    Mol Ther; 2007 Sep; 15(9):1677-85. PubMed ID: 17565352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells.
    Dobrzynski E; Fitzgerald JC; Cao O; Mingozzi F; Wang L; Herzog RW
    Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4592-7. PubMed ID: 16537361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.
    Kay MA; Rothenberg S; Landen CN; Bellinger DA; Leland F; Toman C; Finegold M; Thompson AR; Read MS; Brinkhous KM
    Science; 1993 Oct; 262(5130):117-9. PubMed ID: 8211118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
    Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
    Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscle as a target for supplementary factor IX gene transfer.
    Hoffman BE; Dobrzynski E; Wang L; Hirao L; Mingozzi F; Cao O; Herzog RW
    Hum Gene Ther; 2007 Jul; 18(7):603-13. PubMed ID: 17594244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.
    Mingozzi F; Liu YL; Dobrzynski E; Kaufhold A; Liu JH; Wang Y; Arruda VR; High KA; Herzog RW
    J Clin Invest; 2003 May; 111(9):1347-56. PubMed ID: 12727926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for hemophilia B: AAV-mediated transfer of the gene for coagulation factor IX to human muscle.
    Larson PJ; High KA
    Adv Exp Med Biol; 2001; 489():45-57. PubMed ID: 11554590
    [No Abstract]   [Full Text] [Related]  

  • 16. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete deletion of factor IX gene and inhibition of factor IX activity in a labrador retriever with hemophilia B.
    Brooks MB; Gu W; Ray K
    J Am Vet Med Assoc; 1997 Dec; 211(11):1418-21. PubMed ID: 9394892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic control elements promote long-term expression of human coagulation factor IX gene in hydrodynamically transfected mice.
    Kim HS; Kim JC; Lee YK; Kim JS; Park YS
    J Gene Med; 2011 Jul; 13(7-8):365-72. PubMed ID: 21710610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.
    Arruda VR; Schuettrumpf J; Herzog RW; Nichols TC; Robinson N; Lotfi Y; Mingozzi F; Xiao W; Couto LB; High KA
    Blood; 2004 Jan; 103(1):85-92. PubMed ID: 12969984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer.
    Cooper M; Nayak S; Hoffman BE; Terhorst C; Cao O; Herzog RW
    Hum Gene Ther; 2009 Jul; 20(7):767-76. PubMed ID: 19309290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.